Arrojo Arias E, Mora Navarro G, Abón Santos A, Araujo Luis M S, Capdevila Gallego C, Gutiérrez Torres M J
Médico de familia. EAP Orcasitas. Madrid. Spain.
Aten Primaria. 2002 Sep 30;30(5):284-9. doi: 10.1016/s0212-6567(02)79029-x.
To evaluate the knowledge, attitudes and difficulties of family doctors in the indication of oral anti-coagulation treatment (OCT) in patients with non-valvular auricular fibrillation (NVAF).
Transversal descriptive study.Setting. Area 11 of Madrid primary care.Participants. 250 doctors by simple randomised sampling.
After a pilot study at a health centre, mailing of a questionnaire with a subsequent re-mailing. This collected social and personal details, knowledge of the question, attitudes and difficulties.
157 (62.8%) replied; 91 were women (58.0%); mean age was 39 (SD, 6.0). 97 had reviewed the question recently (61.8%). 110 thought that the anti-aggregation criteria were clear (70.1%; CI, 62.2-77.0%), 107 that the oral anti-coagulation criteria were (68.2%; CI, 60.2-75.2%), 132 that the OCT risks were (84.1%; CI, 77.2-89.2%), and 74 that risk factors of cerebrovascular accident were clear (47.1%; CI, 39.2-55.2%). Initially 96 doctors gave anti-aggregants and referred to cardiology (61.1%; CI, 53.0-68.7%), and 29 began OCT (18.5%; CI, 12.9-25.6%). 134 thought that we avoided initiating OCT (85.3%; CI, 78.6-90.3%), giving as the main reasons the difficulty of monitoring and of requesting further tests, the risks involved and OCT not being up-to-date.
Most professionals have the criteria for OCT in NVAF clear, although they continue to avoid the initiation of OCT. The majority approach is to give anti-aggregants and refer to Cardiology, given the risk of the therapy and the difficulties involved in monitoring and requesting further tests.
评估家庭医生在非瓣膜性心房颤动(NVAF)患者口服抗凝治疗(OCT)适应证方面的知识、态度及困难。
横断面描述性研究。
马德里初级保健第11区。
通过简单随机抽样选取250名医生。
在一家健康中心进行预试验后,邮寄问卷并随后再次邮寄。问卷收集社会和个人详细信息、对该问题的了解、态度及困难。
157人(62.8%)回复;91人为女性(58.0%);平均年龄为39岁(标准差6.0)。97人最近复习过该问题(61.8%)。110人认为抗聚集标准明确(70.1%;95%置信区间,62.2 - 77.0%),107人认为口服抗凝标准明确(68.2%;95%置信区间,60.2 - 75.2%),132人认为OCT风险明确(84.1%;95%置信区间,77.2 - 89.2%),74人认为脑血管意外危险因素明确(47.1%;95%置信区间,39.2 - 55.2%)。最初,96名医生给予抗聚集药物并转诊至心脏病科(61.1%;95%置信区间,53.0 - 68.7%),29名医生开始OCT治疗(18.5%;95%置信区间,12.9 - 25.6%)。134人认为应避免开始OCT治疗(85.3%;95%置信区间,78.6 - 90.3%),主要原因是监测困难、要求进一步检查困难、治疗存在风险以及OCT不够完善。
大多数专业人员对NVAF患者的OCT标准明确,尽管他们仍避免开始OCT治疗。鉴于治疗风险以及监测和要求进一步检查的困难,大多数医生的做法是给予抗聚集药物并转诊至心脏病科。